ALVR AI Analysis Overview
Keys for Bullish View
- Value≥4
- Dividend≥2
Analysis Conclusion
The stock has a lower value rating; if aiming for value investing, existing long-term positions might require gradual reduction.
ALVR Current Performance
2.24%
Allovir inc
1.19%
Avg of Sector
1.11%
S&P500
Top 10 High Relevance to ALVR
| Symbol | Company Name | Value | Trend | Swing Trading | Whale Interest | Dividend | Add to Watchlist |
|---|---|---|---|---|---|---|---|
ANRO | Alto neuroscience inc | - | 3 | 2 | 3 | 1 | |
BLUE | Bluebird bio inc | 4 | 3 | 2 | 1 | 1 | |
KRON | Kronos bio inc | 2 | 5 | 3 | 1 | 1 | |
EDIT | Editas medicine inc | 3 | 3 | 2 | 2 | 1 | |
CARA | Cara therapeutics inc | 2 | 3 | 5 | 1 | 1 |
- ANRO Alto neuroscience incValue -Trend 3Swing Trading 2Whale Interest 3Dividend 1See more
ALVR Profile
AlloVir, Inc. is an allogeneic T cell immunotherapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company's proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. Its technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. Its lead product candidate, posoleucel, is a multi-VST therapy that targets six viruses: adenovirus (BKV), cytomegalovirus (EBV), human herpesvirus 6 (HHV-6) and JC virus (JCV). Its proprietary VST manufacturing platform enables the rapid, robust and reproducible generation of single-virus and multi-virus specific cell therapeutic candidates for clinical use.